Office Technology

Showing 4094 articles
Business

Merck Navigates Mixed Q4 2025 with Oncology Strength Offsetting Vaccine Slump, Sets Cautious 2026 Outlook

Merck & Co. reported a 5% rise in Q4 2025 revenue to $16.4 billion, powered by its blockbuster cancer drug Keytruda and animal health division. However, a steep 35% drop in Gardasil sales, attributed to weakened demand in Asia, highlighted regional vulnerabilities. The pharmaceutical giant issued initial 2026 guidance projecting modest growth while absorbing a significant one-time charge from its recent Cidara Therapeutics acquisition.

Business

Ondas Holdings: A Valuation Puzzle After Stellar Long-Term Gains and Recent Cooling

Shares of Ondas Holdings (ONDS) are under the microscope as investors weigh its dramatic long-term returns against a recent pullback. With the stock trading at a significant discount to some fair value estimates, the debate centers on whether this represents a buying opportunity or reflects justified concerns over execution risks in its wireless and autonomous systems business.